Orchid Pharma Q2 FY27 Net Profit ₹367.6 Crore, Revenue ₹341.3 Crore
Orchid Pharma reported unaudited standalone Q2 FY27 profit before tax of ₹367.6 crore on total income of ₹3,699.0 crore. Consolidated profit before tax was ₹268.4 crore on total income of ₹3,590.2 crore. For the half-year ended September 30, 2026, consolidated profit before tax was ₹294.9 crore.
The results show improved profitability and revenue, which is positive for the company. However, the impact is considered medium as it is a routine financial disclosure without extraordinary events.
The company reported a significant increase in profit before tax for the quarter and half-year ended September 30, 2026, compared to the previous year, indicating strong financial performance.
Orchid Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors, in a meeting held on November 14, 2026, approved these results.
For the quarter ended September 30, 2026, the company reported a profit before tax of ₹3,675.93 lakhs (₹367.6 crore) and total income of ₹36,989.74 lakhs (₹3,699.0 crore) on a standalone basis. Consolidated profit before tax stood at ₹2,683.69 lakhs (₹268.4 crore) with total income at ₹35,902.24 lakhs (₹3,590.2 crore).
On a consolidated basis for the half-year ended September 30, 2026, the company posted a profit before tax of ₹2,948.64 lakhs (₹294.9 crore) and total income of ₹66,502.21 lakhs (₹6,650.2 crore).
The auditors, M/s. Singhi & Co., have issued an unmodified conclusion on the financial results.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.